Altimmune (ALT) Current Leases (2020 - 2026)
Altimmune (ALT) posted quarterly Current Leases of $265000.0 for Q1 2026, up 8.16% year-over-year from $245000.0 in Q1 2025, and up 3.52% quarter-over-quarter from $256000.0 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Current Leases (2020 - 2026) Analysis & Trends
Altimmune (ALT) has reported Current Leases for 7 consecutive years, with $265000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 8.16% year-over-year to $265000.0; the TTM figure through Mar 2026 stood at $265000.0 (up 8.16% YoY), while the FY2025 annual figure was $256000.0, down 8.24% from the prior year.
- Current Leases climbed to $265000.0 in Q1 2026 per ALT's latest filing, from $256000.0 in the prior quarter.
- Across five years, Current Leases topped out at $508000.0 in Q1 2024 and bottomed at $239000.0 in Q2 2025.
- Historically, Current Leases has averaged $374176.5 across 5 years, with a median of $421000.0 in 2022.
- Annual changes were most pronounced in 2023 — Current Leases climbed 9.98% — and 2025, when it tumbled 51.77%.
- Altimmune's Current Leases stood at $452000.0 in 2022, then climbed by 9.73% to $496000.0 in 2023, then sank by 43.75% to $279000.0 in 2024, then retreated by 8.24% to $256000.0 in 2025, then climbed by 3.52% to $265000.0 in 2026.
- Business Quant data shows ALT's Current Leases at $265000.0 in Q1 2026, $256000.0 in Q4 2025, and $247000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | 274,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 274,000.00 |
| Mar 31, 2026 | 265,000.00 |
| Dec 31, 2025 | 256,000.00 |
| Sep 30, 2025 | 247,000.00 |
| Jun 30, 2025 | 239,000.00 |
| Mar 31, 2025 | 245,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 345,000.00 |
| Mar 31, 2024 | 508,000.00 |
| Dec 31, 2023 | 496,000.00 |
| Sep 30, 2023 | 485,000.00 |
| Jun 30, 2023 | 474,000.00 |
| Mar 31, 2023 | 463,000.00 |
| Dec 31, 2022 | 452,000.00 |
| Sep 30, 2022 | 442,000.00 |
| Jun 30, 2022 | 431,000.00 |
| Mar 31, 2022 | 421,000.00 |
| Dec 31, 2021 | 411,000.00 |
| Dec 31, 2020 | 356,716.00 |